; and (iv) ensure that such team receives permission from each health care organization involved to— (I) enter health care facilities participating in the study; and (II) communicate with staff, health care providers, patients, vendors, suppliers, contractors, equipment manufacturers, and members of the Board. (C) Appropriate type of study The Director of the Study Division shall— (i) create guidelines and criteria to determine the appropriate type of study to be conducted or supported, including whether the study should be virtual, in-person, or a special board of inquiry; and (ii) in creating such guidelines and criteria, take into account the impact of the patient safety events to be studied, whether such patient safety events may indicate a systemic risk, and what may potentially be learned from the study. (D) Novel infection and emerging pandemics In the case of a novel infection and emerging pandemic, the Director of the Study Division, in coordination with the Director of the Centers for Disease Control and Prevention, may establish a special board of inquiry— (i) to provide independent recommendations on a coordinated national preparedness and response plan; (ii) to independently monitor the implementation of the preparedness and response plan; and (iii) to recommend technologies to support logistics and autonomous real-time research to inform evidence-based treatment options and decisions. (4) Reporting The Director of the Study Division shall— (A) provide for the submission to the Board and the Patient Safety Research and Development Division of— (i) at least one progress report on each study under this subsection over the course of the study; and (ii) a final report upon the conclusion of the study to inform the Patient Safety Research and Development Division’s recommendations and solutions to prevent patient safety events